A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine

Although treatment options for melanoma patients have expanded in recent years with the approval of immunotherapy and targeted therapy, there is still an unmet need for new treatment options for patients that are ineligible for, or resistant to these therapies. BH3 mimetics, drugs that mimic the act...

Descripción completa

Detalles Bibliográficos
Autores principales: Dart, Chiara R., Mukherjee, Nabanita, Amato, Carol M., Goulding, Anabel, MacBeth, Morgan, Van Gulick, Robert, Couts, Kasey L., Lambert, James R., Norris, David A., Robinson, William A., Shellman, Yiqun G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399604/
https://www.ncbi.nlm.nih.gov/pubmed/34451846
http://dx.doi.org/10.3390/ph14080749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399604/
https://www.ncbi.nlm.nih.gov/pubmed/34451846
http://dx.doi.org/10.3390/ph14080749

Ejemplares similares